Count Me In Launches tRCC Patient Research Project

Mar. 11, 2025 /Count Me In Communications/ — Count Me In has launched a new patient-partnered research project focused on translocation renal cell carcinoma (tRCC), a rare kidney cancer. The tRCC Project enables patients to securely share their unique health data and experiences online to accelerate research and the development of new treatments.

Stellaromics Secures Significant Funding to Advance 3D Spatial Biology

BOSTON, Feb. 11, 2025 /PRNewswire/ — Stellaromics announced an $80M Series B funding round led by Catalyst4. The investment will support the debut of Pyxa, an innovative platform built on STARmap and RIBOmap technologies that enables detailed 3D analysis of thick tissue samples.

EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility

REDWOOD CITY, Calif., Jan. 29, 2025 /BUSINESS WIRE/ — EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development.